InMode Ltd. Ordinary Shares (INMD)
Stock · NASDAQ · Health Care
$14.17as of 10/16/2026
Price chart
Active signals
INMD Signal Track Record
How signals performed across all stocks →What INMD's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -1.3% | 44% | July 9, 2026 |
| Bollinger Band Breakout | 24 | -1.1% | 42% | June 24, 2026 |
| 200-Day Moving Average Touch | 19 | -3.2% | 42% | September 17, 2026 |
| Bollinger Band Breakdown | 15 | -1.8% | 33% | September 16, 2026 |
| Any 20-session window (baseline) | -1.3% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About INMD
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States, Europe, Asia, and internationally. It offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body an…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 660
- Website
- inmodemd.com/
Fundamentals
- 1-day range
- $14.29$14.48
- Market cap
- $957.98M
- P/E (trailing)
- 10.66
- P/E (forward)
- 10.44
- EPS (trailing)
- $1.23
- Dividend yield
- —
- Beta
- 1.99
- Avg. volume
- 474.7K
Forecasts
3 analyst ratings
InMode Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- INMDInMode Ltd. Ordinary Shares$14.16▼ 1.12%Market cap $957.98MP/E 10.66$12.72$16.67
- CBLLCeriBell Inc. Common Stock$25.04▼ 9.41%Market cap $692.45MP/E —$10.85$26.63
- CNMDCONMED Corporation Common Stock$46.72▼ 0.89%Market cap $1.49BP/E 25.13$31.44$53.66
- CVCapsoVision Inc. Common Stock$6.53▲ 1.24%Market cap $344.75MP/E —$4.46$15.37
- FOCLEDAP TMS S.A. American Depositary Shares$4.09▼ 0.97%Market cap $228.65MP/E —$3.99$6.4
- STXSStereotaxis Inc. Common Stock$1.01▼ 3.81%Market cap $133.19MP/E —$1.02$3.2
- VANIVivani Medical Inc. Common Stock (DE)$1.12▼ 2.61%Market cap $117.28MP/E —$0.9227$1.92
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| INMD InMode Ltd. Ordinary Shares | $957.98M | 10.66 | $14.16 | ▼ 1.12% | $12.72$16.67 |
| CBLL CeriBell Inc. Common Stock | $692.45M | — | $25.04 | ▼ 9.41% | $10.85$26.63 |
| CNMD CONMED Corporation Common Stock | $1.49B | 25.13 | $46.72 | ▼ 0.89% | $31.44$53.66 |
| CV CapsoVision Inc. Common Stock | $344.75M | — | $6.53 | ▲ 1.24% | $4.46$15.37 |
| FOCL EDAP TMS S.A. American Depositary Shares | $228.65M | — | $4.09 | ▼ 0.97% | $3.99$6.4 |
| STXS Stereotaxis Inc. Common Stock | $133.19M | — | $1.01 | ▼ 3.81% | $1.02$3.2 |
| VANI Vivani Medical Inc. Common Stock (DE) | $117.28M | — | $1.12 | ▼ 2.61% | $0.9227$1.92 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- InMode Sees Q3 Sales $91.800M-$92.000M vs $91.600M Estbenzinga · 10/13/2026
- InMode: Hope Is Not An Effective Investment Strategy, But Neither Is DespairSeekingAlpha · 9/25/2026
- InMode: Reasonably Valued But With Too Much DramaSeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Itzkovich Moshe · August 4, 2026 · Grant14.0K
- Kenneth Nadav · July 30, 2026 · Grant2.0K
- Nass Shlomo · July 30, 2026 · Grant2.0K
- Ron Hadar · July 30, 2026 · Grant2.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
InMode Sets Q3 2026 Revenue Guidance at $91.8-$92.0M
InMode announced it will report Q3 2026 results on Nov. 11, projecting revenue of $91.8‑$92.0 million, in line with analyst expectations. The company also reaffirmed its full‑year 2026 sales guidance of $365‑$375 million. Current technical indicators show an RSI of 45.4 and support at $14.16, with high‑beta activity suggesting potential volatility.
InMode Sets Q3 2026 Revenue Guidance at $91.8-$92.0M. InMode announced it will report Q3 2026 results on Nov. 11, projecting revenue of $91.8‑$92.0 million, in line with analyst expectations. The company also reaffirmed its full‑year 2026 sales guidance of $365‑$375 million. Current technical indicators show an RSI of 45.4 and support at $14.16, with high‑beta activity suggesting potential volatility.